Background: Acetazolamide (AA) is used to determine the cerebral vasoreactivity (CVR). To investigate whether the usually applied standard dose of 1 g intravenously will guarantee stable test conditions, the dose-response relationship of AA on cerebral blood flow (CBF) and cerebral blood flow velocity (CBFV) in normal subjects was determined. Methods: In 59 healthy volunteers, rCBF was measured with a 133Xenon inhalation device, and CBFV of the middle cerebral artery (MCA) by transcranial Doppler sonography. The first CBF measurement was taken at rest, the second 15 min after application of AA at a dosage of 5, 10, 13, 15 and 18 mg/kg of body weight, respectively. The CBFV (n = 52) of the middle cerebral artery on the side of the better temporal window was taken 25 min after application of AA 13 mg/kg. In order to determine the side effects of AA, statements of an additional 172 patients were included. Results: A significant dosage dependence of AA on the CBF (fast flow and initial slope index) exists between 5 and 18 mg/kg intravenously. After AA 13 mg/kg, the fast flow increases from 70.8 ± 10.8 to 110.1 ± 13.5 ml/100 g/min, the initial slope index from 46.5 ± 5.4 to 62.8 ± 5.8, and the CBFV from 51.5 ± 8.5 to 85.4 ± 14.2 cm/s. The CVR of CBF and CBFV ascertained that way shows an age dependence equivalent to the situation at rest. Severity and frequency of side effects are dosage-dependent, significantly in part, but reversible without exception. Conclusion: For the determination of CVR of CBF with AA, a dosage related to body weight is required. The usually applied standard dose of 1 g intravenously is not sufficient for standardized test conditions. For evaluation of the results obtained, the apparent age dependence of CVR must be taken into account. Because of the severity of side effects occurring at a higher dose, an AA dosage of 13 mg/kg intravenously is recommended.

Keywords:
Cerebral blood flow, Cerebral vasoreactivity, Acetazolamide
1.
Vorstrup S, Henriksen L, Paulson OB: The effect of acetazolamide on cerebral blood flow and cerebral metabolic rate for oxygen. J Clin Invest 1984;74:1634–1639.
2.
Symon L, Held K, Dorsch NWC: A study of regional autoregulation in the cerebral circulation to increased perfusion pressure in normocapnia and hypercapnia. Stroke 1973;4:139–147.
3.
Severinghaus JW, Cotev S: Carbonic acidosis and cerebral vasodilation after diamox. Scand J Lab Invest Suppl 1968;102:I:E.
4.
Ehrenreich DL, Burns RA, Alman RW, Fazekas JF: Influence of acetazolamide on cerebral blood flow. Arch Neurol 1961;5:125–130.
5.
Posner JB, Plum F: The toxic effect of carbon dioxide and acetazolamide in hepatic encephalopathy. J Clin Invest 1960:39:1246–1250.
6.
Cotev S, Lee J, Severinghaus JW: The effects on cerebral blood flow and cerebral tissue pO2. Anaesthesiology 1968;29:471–477.
7.
Laux BE, Raichle ME: The effects of acetazolamide on cerebral blood flow and oxygen utilisation in the rhesus monkey. J Clin Invest 1978;62:585–592.
8.
Hauge A, Nicolaysen G, Thoresen M: Acute effects of acetazolamide on cerebral blood flow in man. Acta Physiol Scand 1983;117:233–239.
9.
Vorstrup S, Brun B, Lassen N: Evaluation of the cerebral vasodilatory capacity by the acetazolamide test before EC-IC bypass surgery in patients with occlusion of the internal carotid artery. Stroke 1986;17:1291–1298.
10.
Vorstrup S: Tomographic cerebral blood flow measurements in patients with ischemic cerebrovascular disease and evaluation of the vasodilatory capacity by acetazolamide test. Acta Neurol Scand Suppl 1988;114:1–48.
11.
Sorteberg W, Lindegaard KF, Rootwelt K, Dahl A, Nyberg-Hansen R, Russell D, Nornes H: Effects of acetazolamide on cerebral artery blood velocity and regional cerebral blood flow in normal subjects. Arch Neurochir 1989;97:139–145.
12.
Piepgras A, Schmiedeck P, Leinsinger PG, Haberl RL, Kirsch CM, Einhäupl KM: A simple test to assess cerebrovascular reserve capacity using transcranial Doppler sonography and acetazolamide. Stroke 1990;21:1306–1311.
13.
Ringelstein EB, Van Eyck S, Mertens I: Evaluation of cerebral vasomotor reactivity by various vasodilating stimuli: Comparison of CO2 to acetazolamide. J Cereb Blood Flow Metab 1992;12:162–168.
14.
Kleiser B, Scholl D, Widder B: Assessment of cerebral vascular reactivity by Doppler CO2 and Diamox testing: Which is the appropriate method? Cerebrovasc Dis 1994;4:134–138.
15.
Obrist WD, Thompson HK, Wang HS, Wilkinson HE: Regional cerebral blood flow estimated by 133Xenon inhalation. Stroke 1975;6:245–256.
16.
Risberg J, Prohovnik I: rCBF measurements by 133Xenon inhalation: Recent methodological advances. Prog Nucl Med 1981;11:342–347.
17.
Maximilian VA, Prohovnik I, Risberg J: Cerebral hemodynamic response to mental activation in normo- an hypercapnia. Stroke 1980;11:342–347.
18.
Sullivan HG, Kingsbury TB, Morgan ME, Jeffcoat RD, Allison JD, Goode JJ, McDonnell DE: The rCBF response to diamox in normal subjects and cerebrovascular disease patients. J Neurosurg 1987;67:525–534.
19.
Dahl A, Russell D, Rootwelt K, Nyberg-Hansen R, Kerty E: Cerebral vasoreactivity assessed with transcranial Doppler and regional blood flow measurements. Stroke 1995;26:2302–2306.
20.
Kreisig T, Schmiedeck P, Leinsinger G, Einhäupl K, Moser E: 133Xe-DSPECT: Normal values of cerebral blood flow at rest and of reserve capacity. Nuklearmedizin 1987;26:192–197.
21.
Meyer JS, Ishihara N, Deshmukh VD: Improved method for noninvasive measurement of regional cerebral blood flow by 133Xe inhalation. I. Description of method and normal values obtained in healthy volunteers. Stroke 1978;9:195–205.
22.
Melamed E, Lavy S, Bentin S, Cooper G, Rinot Y: Reduction of regional cerebral blood flow during normal aging in man. Stroke 1980;11:31–35.
23.
Arnolds BJ, von Reutern RM: Transcranial Doppler sonography. Examination technique and normal reference values. Ultrasound Med Biol 1986;12:115–123.
24.
Davis SM, Ackerman RH, Correia JH, Alpert NM, Chang J, Buonanno F, Kelley RE, Rosner B, Taveras JM: Cerebral blood flow and cerebrovascular CO2 reactivity in stroke age normal controls. Neurology 1983;33:391–399.
25.
Tsuda Y, Hartmann A: Changes of hyperfrontality of cerebral blood flow and carbon dioxide reactivity with age. Stroke 1989;20:1667–1673.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.